Left Atrial Appendage Closure Techniques: 2015
|
|
- Francis Pitts
- 5 years ago
- Views:
Transcription
1 Left Atrial Appendage Closure Techniques: 2015 Ramon Quesada, MD, FACP, FACC, FSCAI Medical Director, Interventional Cardiology & Cardiac Research Medical Director, Structural Heart and TAVR Program Baptist Cardiac & Vascular Institute, Miami, Florida Clinical Associate Professor of Medicine, Florida International University Herbert Wertheim School of Medicine
2 Ramon Quesada, MD, FACP, FACC,FSCAI, FCCP Speakers Bureau: Medtronic, Abbott, BSC Consultant/Advisory Board: Abbott
3 Atrial Fibrillation A major source of cardiogenic embolismrelated stroke 500,000 strokes per year AHA estimates that 15 20% of strokes/year are related to AF 90% of thrombus originate in LAA Source: Neurology, 1978; Stroke, 1985; European Heart Journal, 1987; Lancet, 1987
4 Fibrillation causes blood to stagnate in the LAA The stagnant blood becomes an ideal environment for a thrombus or blood clot to form The blood clot, or portion of it, dislodges from the LAA and travels through arterial system The embolism lodges itself in the blood vessels of the brain, restricting blood flow and causing a stroke Thrombus in the LAA Images on file at Boston Scientific Corporation 1 Blackshear JL. Odell JA., Annals of Thoracic Surgery. 1996;61:
5 CHA 2 DS 2 VASc is a newer scoring system Risk of Stroke CHA 2 DS 2 VASc, developed by Lip et al, is a refinement of the older CHADS 2 Score which includes additional stroke risk factors and puts greater emphasis on age as a risk factor 1 Condition/Risk Factor Points C Congestive heart failure 1 H Hypertension 1 A Age 75 years 2 D Diabetes mellitus 1 S 2 Previous stroke or TIA 2 V Vascular disease 1 A Age years 1 Sc Sex (female gender) 1 European Society of Cardiology Guidelines 2 CHA 2 DS 2 -VASc Score Treatment 18% 15% 12% 9% 6% 3% 0% 0 No treatment 1 Aspirin or warfarin or dabigatran 2 Warfarin or dabigatran 1. Lip GY et al, Chest. 2010;137(2): Camm AJ et al, Eur Heart J. 2010;31: Annual Risk of Stroke 9.8% 9.6% 6.7% 6.7% 3.2% 4.0% 1.3% 2.2% 0.0% 15.2% CHA 2 DS 2 VASc Score
6 An Alternative to Medical Therapy: Percutaneous Closure of Left Atrial Appendage for Stroke Prevention in Non-Valvular Afib Patients
7 Interventions with the LAA: Clinical Studies Today Ligation, Clips, and Endovascular Options LAA Clip Surgical Ligation EXCLUDE Trial (completed) AtriClip Device was FDA approved in 2010 for LAA closure No specific indication for Stroke Reduction ClinicalTrials.gov identifier: NCT LAA Closure (LAAC) Devices Currently No FDA approved LAAC device O PLAATO First LAAC device (2001) Device no longer available WATCHMAN Safety and Efficacy of Left Atrial Appendage Occlusion Devices Observational Study (retrospective) To compare LARIAT vs. WATCHMAN LARIAT currently does not have a specific indication for LAA Closure or Stroke Reduction 2 Completed Trials: PROTECT AF Trial PREVAIL Trial ClinicalTrials.gov identifiers: NCT (PROTECT AF) NCT (PREVAIL) ClinicalTrials.gov identifier: NCT ACP First trial begun in 2013 AMPLATZER C ardiac Plug Clinical Trial ClinicalTrials.gov identifier: NCT Caution: In the US, WATCHMAN is an investigational device, limited by applicable law to investigational use only and not available for sale. CE Mark 2005
8 Threaded Insert Experience with WATCHMAN LAA Closure Device PET fabric Frame: Nitinol structure Available sizes: 21, 24, 27, 30, 33 mm (diameter) 10 Fixation barbs around device perimeter engage LAA tissue Barbs Contour shape accommodates most LAA anatomy Threaded Insert Fabric Cap: (PET) Fabric Polyethyl terephthalate Prevents harmful emboli from exiting during the healing process Barbs 160 micron filter
9 Overview: WATCHMAN Implantation Procedure
10 WATCHMAN Evidence-Based Medicine 2002 Pilot Endpoints: Feasibility and Safety Comparison: nonrandomzed Incl/Excl: CHADS 2 1, able to tolerate warfarin 2008 CAP Registry Endpoints: Collect additional safety and efficacy data to be pooled with PROTECT AF Incl/Excl: same as PROTECT AF 2010 PREVAIL Endpoint: Safety and Efficacy Comparison: warfarin Incl/Excl: CHADS 2 2, some exceptions for CHADS 2 =1 no clopidegrel 7 days prior to procedure 2012: ESC Guidelines & Expanded Indication 2009 ASAP Endpoint: Efficacy 2005 PROTECT AF Comparison: CHADS 2 score expected stroke rate Endpoints: Safety and Efficacy Incl/Excl: intolerant or contra-indicated for warfarin Comparison: warfarin Incl/Excl: CHADS 2 1, able to tolerate warfarin 2013 EMEA Registry* Endpoint: Additional information in a real-world setting Incl/Excl: All comers SH AA
11 WATCHMAN Clinical Study Experience STUDY PATIENTS SITES COMMENTS Pilot 66 8 PROTECT AF Continued Access Registry (CAP) ASAP* patient years of follow-up 30 patients with 5+ years of follow-up 1,500 patient years of follow-up 27 months average follow-up per patient Significantly improved safety results Treat patients contraindicated for warfarin EVOLVE* 37 3 Evaluate next generation WATCHMAN Total 1,563 PREVAIL Same endpoints as PROTECT AF Revised inclusion/exclusion criteria Initiate enrollment November 2010 *European enrollment sites only
12 PROTECT AF 4 Year Follow Up: Primary Efficacy Endpoint SH AA
13 Rate per 100 patient years PROTECT AF Long Term (4 Year Follow-up) Events in PROTECT AF trial at 2,621 patient years % lower 60% lower 34% lower P S = Primary Efficacy P= CV or Unexplained Death P= All-Cause Death WATCHMAN Group N=463 Warfarin Group N=244 Ps = Posterior Probability for Superiority All three endpoints met statistical superiority SH AA
14 Cohort Data from PROTECT AF Intent-to-Treat: Primary Safety Results Reflects the risks of the Intervention WATCHMAN Rate (95% CI) Control Rate (95% CI) Rel. Risk (95% CI) 600 pt-yrs , , , pt-yrs , , , pt-yrs , , , pt-yrs , , , pt-yrs , , , 2.70 Higher upfront risk associated with the procedure Higher relative risk in terms of safety
15 Primary Safety Kaplan-Meier Estimates Event Free Probability Watchman Control Control Watchman Days from Randomization Cohort 1 Year Event Rate (95% CI) 2 Year Event Rate (95% CI) 3 Year Event Rate (95% CI) WATCHMAN 10.1 (7.4, 12.9) 10.4 (7.6, 13.2) 13.6 (9.9, 17.4) Control 4.3 (1.7, 6.9) 6.7 (3.4, 10.0) 8.9.(4.8, 12.9) 1500 Patient-year Analysis
16 What Are these Events and Why are they Happening? Procedure Related Pericardial Effusion / Tamponade Procedure-related stroke Device embolization Bleeding events (mostly associated with Control Group) Intracranial or GI bleeding requiring transfusions 1 bleeding event on device arm while patient was on Coumadin post implant
17 Next Step: Registry More Safety Data from Enrollment in CAP Registry 26 centers continued enrolling in non-randomized CAP registry Gained more experience with procedure Safety data demonstrates the learning curve associated with the procedure Data shows that risks of the procedure have been mitigated
18 Procedure & Implant Success Rates PROTECT AF vs. CAP Procedure Time (Mean ± SD) PROTEC T AF PROTECT AF Early Late CAP p- value* p- value± 62±34 67±36 58±33 50±21 <0.001 <0.001 Implant Success 485/542 (89.5%) 239/271 (88.2%) 246/271 (90.8%) 437/460 (95%) *From tests comparing the PROTECT AF cohort with CAP ±From tests for differences across three groups (early PROTECT AF, late PROTECT AF, and CAP) Implant success defined as attempted case resulting in successful implantation
19 Safety Event Rates in PROTECT AF and CAP PROTECT AF PROTECT AF Early Late CAP p-value* p-value± Proc/Device Rel. Safety AE w/in 7 days 42/542 (7.7%) 27/271 (10%) 15/271 (5.5%) 17/460 (3.7%) Serious pericardial effusion w/in 7 days 27/542 (5%) 17/271 (6.3%) 10/271 (3.7%) 10/460 (2.2%) Proc. Rel. Stroke 5/542 (0.9%) 3/271 (1.1%) 2/271 (0.7%) 0/460 (0%) *From tests comparing the PROTECT AF cohort with CAP ±From tests for differences across three groups (early PROTECT AF, late PROTECT AF, and CAP) The 5 procedure related strokes were air embolisms during procedure Reduced to 0% in CAP from improved air management techniques
20 Primary Safety Kaplan-Meier Estimates CAP PROTECT AF Late PROTECT AF Early
21 Demographics: Device Patients Characteristic Age, years PROTECT AF N= ± 8.8 (463) (46.0, 95.0) CAP N= ± 8.3 (566) (44.0, 94.0) PREVAIL N= ± 7.4 (269) (50.0, 94.0) P value <0.001 Gender (Male) 326/463 (70.4%) 371/566 (65.5%) 182/269 (67.7%) CHADS 2 Score (Continuous) CHADS 2 Risk Factors 2.2 ± 1.2 (1.0, 6.0) 2.5 ± 1.2 (1.0, 6.0) 2.6 ± 1.0 (1.0, 6.0) CHF 124/463 (26.8%) 108/566 (19.1%) 63/269 (23.4%) Hypertension 415/463 (89.6%) 503/566 (88.9%) 238/269 (88.5%) Age /463 (41.0%) 293/566 (51.8%) 140/269 (52.0%) Diabetes 113/463 (24.4%) 141/566 (24.9%) 91/269 (33.8%) Stroke/TIA 82/463 (17.7%) 172/566 (30.4%) 74/269 (27.5%) Most notable differences: Age, Diabetes, and Prior Stroke/TIA <0.001 SH AA PROTECT AF and CAP data from Reddy, VY et al. Circulation. 2011;123:
22 PREVAIL Trial: Co-Primary Endpoints One-sided 95% upper CI bound for success 2.2% 2.67% 2.618% 95% upper CI bound for non-inferiority % upper CI bound for non-inferiority % 2.5% 3.0% Percent of patients experiencing an event Acute (7-day) occurrence of death, ischemic stroke, systemic embolism and procedure or device related complications requiring major cardiovascular or endovascular intervention month Rate Ratio 2.0 Comparison of composite of stroke, systemic embolism, and cardiovascular/unexplained death Similar 18-month event rates in both control and device groups = month Rate Difference Comparison of ischemic stroke or systemic embolism occurring >7 days post randomization Endpoint success in the presence of an over performing control group Endpoint Success; 6 events in device group = 2.2% (6/269) Results are preliminary; final validation not yet complete PREVAIL Results from David Holmes, MD
23 PREVAIL Control (Warfarin) Group Performance In spite of the high average CHADS 2 score of 2.6 in the control group, the observed rate of stroke in the PREVAIL Control group was lower than in other published warfarin studies PREVAIL control group rate = 0.7 (95% CI 0.1, 5.1) Wide confidence bounds due to small number of patients with 18-months of follow-up Trial Control (Warfarin) Group Stroke, Systemic Embolism Rate (Per 100 PY) PROTECT AF RE-LY (Dabigatran) ARISTOTLE (Apixaban) ROCKET AF (Rivaroxaban) PREVAIL 0.7 Results are preliminary; final validation not yet complete PROTECT AF from Reddy, VY et al. Circulation. 2011;123: PREVAIL Results from David Holmes, MD 1 Ischemic stroke rate from Holmes et al. Lancet 2009; 374: Connolly et al. N Engl J Med 2009; 361: Granger et al. N Engl J Med 2011; 365: Patel et al. N Engl J Med 2011; 365:883-91
24 Despite implantation in higher risk patients the WATCHMAN device was safely implanted by new operators PROTECT AF Implant Success CAP Implant Success PREVAIL Implant Success 90.9% 94.3% 95.0% p = 0.01 % of Successful Implants 90.0% 92.0% 94.0% 96.0% 98.0% Study Implant Success 95% N= 26 Experienced Operators 96.2% N= 24 New Operators 93.2% Implant success defined as deployment and release of the device into the left atrial appendage p = SH AA PROTECT AF and CAP data from Reddy, VY et al. Circulation. 2011;123:
25 % of Patients PREVAIL: 7 Day Serious Procedure/Device Related Complications Composite of vascular complications includes cardiac perforation, pericardial effusion with tamponade, ischemic stroke, device embolization, and other vascular complications % 9.0% 8.7% p = % 7.0% 6.0% 5.0% 4.1% 4.4% 4.0% 3.0% n=39 n=23 n=12 2.0% 1.0% 0.0% PROTECT AF CAP PREVAIL No procedure-related deaths reported in any of the trials PROTECT AF and CAP data from Reddy, VY et al. Circulation. 2011;123: PREVAIL Results from David Holmes, MD
26 % Patients Procedure related safety events Rates of safety events within 7 days of procedure in PROTECT AF and CAP registry Reduction of ~50% in pericardial effusion rates between studies Procedure-related stroke reduced to 0 Of patients experiencing pericardial effusion in CAP, 90% were treated with pericardiocentesis and 10% required surgical intervention PROTECT-AF CAP Reddy VY et al. Circulation. 2011;123:
27 % of Patients % of Patients PREVAIL 4.0% 3.0% Pericardial Effusions and Stroke p = P = PROTECT AF CAP PREVAIL 2.4% 2.0% 1.0% 0.0% 3.0% 2.0% 1.0% 0.0% 1.6% n=7 0.2% 0.4% n=1 n=1 Cardiac perforation requiring surgical repair p = PROTECT AF CAP PREVAIL 1.1% n=5 0.0% 0.4% n=0 n=1 Procedure/Device Related Strokes 1.2% n=11 n=7 1.5% n=4 Pericardial effusion with cardiac tamponade requiring pericardiocentesis or window PROTECT AF and CAP data from Reddy, VY et al. Circulation. 2011;123: PREVAIL Results from David Holmes, MD
28 PREVAIL: Conclusions Despite implantation in higher risk patients the WATCHMAN device was safely implanted by new operators 2 of 3 primary endpoints were met even in the presence of an over performing control group Results of the PREVAIL trial add to the wealth of previously published data on WATCHMAN PREVAIL Results from David Holmes, MD
29 Procedural Risks: We know what they are and we ve learned techniques to reduce their incidence Cardiac Perforation Transeptal crossing Advancement into LAA Device deployment and recapture Periprocedural Stroke Inappropriate Device Placement Poor Seal of LAA Device Embolization
30 Modifications to Device: Have prevented complications or reduced severity of events Technical Improvements Device made shorter, reducing the need to cannulate as deep into LAA New sheath developed Softer tip Markers for guidance into appendage
31 Standardization of Procedure Techniques: Have prevented complications or reduced severity of events Optimized Transeptal access Strict use of pigtail catheter for cannulation of LAA Proper device manipulation Patient Management Reduced ACT levels during procedure Discontinued use of post procedure LMWH
32 Avoiding Cardiac Perforation from Transeptal Crossing Use available imaging tools for safe crossing. TEE in most cases ICE if that is the operator s comfort level Mid to inferior and posterior stick for best approach into LAA Getting across difficult septums RF energy for crossing
33 Avoiding Cardiac Perforation While Accessing the LAA Use of the Pigtail catheter Start contrast injection at ostium for full visualization of LAA
34 Angiographic Assessment in Two Views RAO Caudal and Cranial Use multiple imaging planes to understand the anatomy and plan the approach Distinguish separate lobes to determine optimal placement Using only one view may have them overlap on Cine
35 Deployment Knob Avoiding Cardiac Perforation: Device Manipulation Core Wire Hemostasis Valve Constrained Device Distal Marker Band Careful deployment by not advancing into LAA Watch distal tip of device during deployment and recapture
36 Additional Avoidable Risks: Improper seal of LAA Device embolization Avoiding these scenarios requires understanding of LAA and device imaging During baseline screening After device deployment and prior to release
37 Avoiding Device Placement Complications Requires Understanding the Anatomy
38 Identify an Improper Position Before Releasing: Avoid Leaks, Avoid Embolization Example of inadequate position in posterior lobe Final device placement in anterior lobe Off axis position En face view of device Long axis view of device Face at ostium Canted position Barbs disengaged! Stable position Proper seal
39 Understanding Proper Position Before Releasing: Avoid Leaks, Avoid Embolization Device in improper position Final, stable position and good seal Significant Shoulder Much of device is in the left atrium High angle showing proper orientation at ostium Canted position Coaxial Position
40 Use All Imaging Tools to Confirm Release Criteria Inappropriate Placement Tines compressed distally Rapid filling of contrast into LAA through gaps Inferior shoulder protrusion Final Device Placement Device opened up allowing barbs to make contact Slow filling of contrast through filter cap
41 Benefit of Device Therapy: Localized, single intervention, long term solution to stroke prevention Data shows that the therapy is effective Avoids Risks Associated with Anticoagulants: Continual bleeding risk from drugs Systemic effects of medication Patient compliance issues Difficulties with anticoagulation reversal when needed Long term, these problems continue to increase
42 Patient History 79 YR old female with a history of Chronic Atrial Fibrillation with a high risk for anticoagulation due to two episodes of GI bleeding, one episode while on coumadin and the 2 nd episode on Pradaxa. Most recent hospitalization for lower GI bleeding. PMH: previous embolic CVA with no major sequelae HTN, no Diabetes, non-smoker
43 Planned Therapy Patient was referred for LAA occlusion vs exclusion Patient did not qualify for the PREVAIL study (currently in randomization ~ coumadin vs Watchman device) Therefore patient was offered LAA exclusion with the Lariet device
44 Transeptal catheter in place Lariet delivery sheath advanced over the wire transpericardially
45 Magnet wire is advanced to the tip of the left atrial appendage
46 Magnet wire is advanced to the tip of the left atrial appendage and over the wire the balloon marker is advanced to the neck of the appendage.
47 The two magnets are engaged to position for procedure
48 The Lariet device is advanced over the left atrial appendage
49 The snare is closed excluding the left atrial appendage
50 Final result: Complete exclusion of left atrial appendage
51 ATRIAL SEPTAL OCCLUDER FOR LAA CLOSURE Approval Status: First FDA approved for ASD Closure
52 Patient Hx 77 yr old male with hx of embolic CVA, TIAs, CABG, chronic atrial fibrillation, admitted with a grand mal seizure but is at very high risk for anticoagulation. Eval for Watchman device but was not approved. The patient was not a candidate for the Lariet device because of the previous CABG with no intact pericardium. CHADS score of 4.
53 Trans Septal Access
54 LAA Closure: Pre Angio and Guide Engagement
55 LAA Guide Deep Engagement
56 Device ASO Deployment
57 Device Stability Testing
58 LAA Post Release
59 TEE Post Release
60 What We ve Learned About the Risks of Stroke Prevention There are risks involved with the LAA closure procedure The risks we have seen occur under a controlled environment and can be minimized or prevented There are risks and long term complications with anticoagulation LAA occlusion must be seen as an ALTERNATIVE solution for stroke prevention in AF patients Procedure risks need to be considered under the context of the patient s other options
61 Thank You!
Appendage Closure. Jason Rogers, MD. Director, Interventional Cardiology UC Davis Medical Center Sacramento, California
Appendage Closure Jason Rogers, MD Director, Interventional Cardiology UC Davis Medical Center Sacramento, California Left Atrium: Atrial Fibrillation Left Atrial Appendage Left Atrium Incidence of Atrial
More informationWatchman. Left Atrial Appendage Closure Device. Uniquely engineered for the LAA 1-3 with proven safety and longterm efficacy. 4-8
TM Watchman Left Atrial Appendage Closure Device PROOF OFLEADERSHIP Uniquely engineered for the LAA 1-3 with proven safety and longterm efficacy. 4-8 Patients with AF have a 5x increased risk of stroke.
More informationOcclusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France
Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France LAA Occlusion Is there a real future? Background Protect AF Trial Other Studies CAP, ASAP, Prevail Left Atrial Appendage
More informationLeft Atrial Appendage Occlusion
Left Atrial Appendage Occlusion A new strategy to prevent stroke in atrial fibrillation Ashok Talreja MD and Arijit Chanda MD VHVI symposium 24th February 2018 Outline of presentation 1. Risk of stroke
More informationRole of cardiac imaging for catheterbased left atrial appendage closure
Role of cardiac imaging for catheterbased left atrial appendage closure Ana G. Almeida, MD, PhD Cardiology University Hospital Santa Maria, Lisbon Ana G. Almeida, MD, PhD, FESC University Hospital Santa
More informationWatchman a Stroke Prevention Technology for Patients with Atrial Fibrillation
Watchman a Stroke Prevention Technology for Patients with Atrial Fibrillation Scripps hospital,la Jolla, CA Atrial fibrillation is a major source of cardiogenic embolic related stroke 500,000 strokes per
More informationLeft Atrial Appendage Occlusion: Shutting Out Embolic Disease Without Anticoagulation
Left Atrial Appendage Occlusion: Shutting Out Embolic Disease Without Anticoagulation Zoltan G. Turi, M.D. Rutgers Robert Wood Johnson Medical School New Brunswick, NJ Disclosure Information Zoltan G.
More informationTHINK OUTSIDE THE PILLBOX
WATCHMAN : A CLINICALLY PROVEN AND SAFE THERAPY FOR YOUR NVAF PATIENTS WATCHMAN reduces the risk of stroke in NVAF patients as effectively as warfarin WATCHMAN also reduces the long-term risk of bleeding
More informationLeft Atrial Appendage Closure: Moving Beyond Blood Thinners to Prevent Stroke in Atrial Fibrillation October 29, 2016
Left Atrial Appendage Closure: Moving Beyond Blood Thinners to Prevent Stroke in Atrial Fibrillation October 29, 2016 Jesse Jorgensen, MD, FACC Director, Cardiac Cath Lab, Greenville Health System Disclosures
More informationDevices to Protect Against Stroke in Atrial Fibrillation
Devices to Protect Against Stroke in Atrial Fibrillation Jonathan C. Hsu, MD, MAS Associate Clinical Professor Division of Cardiology, Section of Cardiac Electrophysiology June 2, 2018 Disclosures Honoraria
More informationPatients selection criteria for LAA occlusion. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Patients selection criteria for LAA occlusion Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Atrial Fibrillation The most common cardiac arrhythmia. Confers
More informationLeft Atrial Appendage Occlusion: A Valid Option to Anticoagulation for Long-term Prevention of Stroke Saibal Kar, MD
Left Atrial Appendage Occlusion: A Valid Option to Anticoagulation for Long-term Prevention of Stroke Saibal Kar, MD Director of Interventional Cardiac Research Cedars Sinai Medical Center Disclosure Statement
More informationTechnique, Risk, and Benefit. T. Santoso University of Indonesia Medical School,
Left Atrial Appendage Closure Technique, Risk, and Benefit T. Santoso University of Indonesia Medical School, Medistra Hospital, Jakarta, Indonesia Percutaneous LAA Closure Devices PLAATO (no longerdeveloped)
More informationLeft Atrial Appendage Occlusion in the Era of Novel Anticoagulants
Left Atrial Appendage Occlusion in the Era of Novel Anticoagulants Saibal Kar, MD, FACC, FSCAI Professor of Medicine Director of Interventional Cardiac Research Heart Institute, Cedars-Sinai Medical Center,
More informationPage 1. Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion. Atrial fibrillation: Scope of the problem
Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion Benjamin A. D Souza, MD, FACC, FHRS Assistant Professor of Clinical Medicine Penn Presbyterian Medical Center Cardiac
More informationLeft Atrial Appendage Closure for Stroke Prevention in Patients with Atrial Fibrillation
Left Atrial Appendage Closure for Stroke Prevention in Patients with Atrial Fibrillation Issam D. Moussa, MD Professor of Medicine Mayo Clinic College of Medicine Chair, Division of Cardiovascular Medicine
More informationWATCHMAN: Where do we stand
Latest Updated on LAAC and Its Clinical Evidence Saibal Kar, MD, FACC, FAHA, FSCAI Associate Professor Heart Institute, t Cedars Sinai i Medical Center, Los Angeles, CA Disclosure Information WATCHMAN:
More informationCryptogenic Stroke: A logical approach to a common clinical problem
Cryptogenic Stroke: A logical approach to a common clinical problem Alphonse M. Ambrosia, DO, FACC Interventional Cardiologist CardioVascular Associates of Mesa Mesa, Arizona Speakers Bureau Boston Scientific
More informationLeft atrial appendage occlusion
Kardiologie Left atrial appendage occlusion Mischa Kühne Kardiolunch, 10.9.2015 Overall stroke rate 5% per year CHA 2 DS 2 VASC score Most AF patients need protection from stroke ESC guidelines AF, 2010/2012
More informationWilliam A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, Pennsylvania USA
William A. Gray MD System Chief of Cardiovascular Services, President, Wynnewood, Pennsylvania USA What does Guilty until Effective mean? A fact is a simple statement that everyone believes. It is innocent
More informationLeft Atrial Appendage Closure
Left Atrial Appendage Closure Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic La Jolla, CA, USA price.matthew@scrippshealth.org Risk Factors for Stroke From The Perspective
More informationLAA Occluders: The Right Device for the Right Patient ACC/SHA MEETING OCTOBER 31 ST 2015 JEDDAH, KSA OMER A. M. ELAMIN, MD, FACC
LAA Occluders: The Right Device for the Right Patient ACC/SHA MEETING OCTOBER 31 ST 2015 JEDDAH, KSA OMER A. M. ELAMIN, MD, FACC INTERVENTIONAL CARDIOLOGIST DIRECTOR, ADULT CARDIOLOGY FELLOWSHIP TRAINING
More informationGauging stroke risk across the AF spectrum and selecting the appropriate patient for LAA closure. Miguel Valderrábano, MD
Gauging stroke risk across the AF spectrum and selecting the appropriate patient for LAA closure Miguel Valderrábano, MD Risk of Stroke in Atrial Fibrillation CHADS 2 -CHA 2 DS 2 -VASc Scores Adjusted
More informationUpdate in Left Atrial Appendage Occlusion: More Options
Update in Left Atrial Appendage Occlusion: More Options Sajjad A Sabir, MD Director, Structural Heart Disease Program Director, Interventional Echocardiography Director, Heart Valve Clinic Non-Valvular
More informationCARDIOLOGY GRAND ROUNDS
CARDIOLOGY GRAND ROUNDS Title: Reintroduction Overview: Watchman Speaker: Mario Goessl, MD, FACC, FAHA, FESC, FSCAI Minneapolis Heart Institute at Abbott Northwestern Hospital Date: Monday, October 24,
More informationLeft Atrial Appendage Closure Devices. Atrial Fibrillation 10/11/2017
Left Atrial Appendage Closure Devices Emile Daoud, MD Chief, Cardiac Electrophysiology Wexner Medical Center, The Ohio State University Atrial Fibrillation 1 Adjusted Annual Stroke Risk Using CHA 2 DS
More informationLeft Atrial Appendage Closure in SCRIPPS CLINIC
Left Atrial Appendage Closure in Atrial Fibrillation to Prevent Stroke Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic La Jolla, CA, USA price.matthew@scrippshealth.org
More informationLeft Atrial Appendage Closure: The Rationale
Left Atrial Appendage Closure: The Rationale JOHN D. HUMMEL, MD DIRECTOR OF CLINCAL ELECTROPHYSIOLOGY RESEARCH PROFESSOR OF CLINICAL INTERNAL MEDICINE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER 1 Disclosures
More informationLeft Atrial Appendage Closure 4 questions Who? When? How? Results?
Left Atrial Appendage Closure 4 questions Who? When? How? Results? David R. Holmes, Jr., M.D. Mayo Clinic, Rochester ACC New York CVS New York, NY December 2017 2012 MFMER slide-1 Presenter Disclosure
More informationPercutaneous Epicardial LAA Closure: When Does it Make Sense?
Percutaneous Epicardial LAA Closure: When Does it Make Sense? Petr Neuzil, MD,PhD, FESC Professor of Medicine Cardiology department Na Homolce Hospital, Prague, Czechia petr.neuzil@gmail.com Disclosures
More informationRole of Imaging in Complex LAA Closure Anatomies
Role of Imaging in Complex LAA Closure Anatomies Sameer Gafoor 1,2 1 Swedish Heart and Vascular: Ming Zhang, Paul Huang, Darryl Wells, Adam Zivin, John Petersen II, Madalena Petrescu, Nimish Muni, Eric
More informationPERCUTANEOUS STRUCTURAL UPDATES TAVR WATCHMAN(LEFT ATRIAL APPENDAGE OCCLUDERS) MITRACLIP PARAVALVULAR LEAK REPAIRS ASD/PFO CLOSURES VALVULOPLASTIES
PERCUTANEOUS STRUCTURAL UPDATES TAVR WATCHMAN(LEFT ATRIAL APPENDAGE OCCLUDERS) MITRACLIP PARAVALVULAR LEAK REPAIRS ASD/PFO CLOSURES VALVULOPLASTIES Dr.Vinny K.Ram No disclosures TAVR 1 Lesson number 1:
More informationTrick or Treat 2: A New Era of Stroke Prevention in AF? WATCHMAN and LARIAT?
Trick or Treat 2: A New Era of Stroke Prevention in AF? WATCHMAN and LARIAT? Disclosure SentreHeart, Inc Consultant Equity holder A cardiac disease that kills by producing emboli The most severe consequence
More informationPREVAIL: 5-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure vs Medical Therapy in Patients With Nonvalvular Atrial Fibrillation
PREVAIL: 5-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure vs Medical Therapy in Patients With Nonvalvular Atrial Fibrillation Dr. Saibal Kar, MD TCT 2017 Late Breaking Clinical
More informationPercutaneous Left Atrial appendage occlusion and anticoagulation therapy Nicolas Lellouche, MD, PhD
Percutaneous Left Atrial appendage occlusion and anticoagulation therapy Nicolas Lellouche, MD, PhD Fédération de Cardiologie Hôpital Henri Mondor Créteil Atrial Fibrillation is a major cause of Stroke
More informationUpdate in Left Atrial Appendage Closure Devices. Faisal Al-Samadi MBBS, FRCPC, FACP, FACC, FSCAI, FHRS
Update in Left Atrial Appendage Closure Devices Faisal Al-Samadi MBBS, FRCPC, FACP, FACC, FSCAI, FHRS Atrial Fibrillation - Overview Higher stroke risk for older patients and those with prior stroke or
More informationListen to Your Heart. What Everyone Needs To Know About Atrial Fibrillation & Stroke. The S-ICD System. The protection you need
Listen to Your Heart The S-ICD System What Everyone Needs To Know About Atrial Fibrillation & Stroke The protection you need without Stroke. touching Are you your at heart risk? Increase your knowledge.
More informationSHARED DECISION MAKING: AN EVIDENCE-BASED CORNERSTONE OF LAAC THERAPY
SHARED DECISION MAKING: AN EVIDENCE-BASED CORNERSTONE OF LAAC THERAPY SHARED DECISION MAKING: AN EVIDENCE BASED CORNERSTONE OF LAAC THERAPY Shared decision making is a collaborative process that allows
More informationAtrial fibrillation (AF), one of the
Hellenic J Cardiol 2013; 54: 408-412 Case Report Left Atrial Appendage Occlusion with the Amplatzer Amulet for Stroke Prevention in Atrial Fibrillation: The First Case in Greece Apostolos Tzikas, Lambros
More informationTHINK OUTSIDE THE PILLBOX
THINK OUTSIDE THE PILLBOX An innovative one-time procedure that reduces the risk of stroke in your non-valvular atrial fibrillation (NVAF) patients and the long-term risk of bleeding that comes with a
More informationAtrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?
Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Nicolas Lellouche Fédération de Cardiologie Hôpital Henri Mondor Créteil Disclosure Statement of Financial Interest I currently
More informationNCVH Birmingham 2013 August 24, Michael S. Bailey, MD Birmingham Heart Clinic
NCVH Birmingham 2013 August 24, 2013 Michael S. Bailey, MD Birmingham Heart Clinic NCVH Birmingham 2015 August 29, 2015 Michael S. Bailey, MD Birmingham Heart Clinic Left Atrial Anatomy Part of a larger
More informationRate or Rhythm Control? Epidemiology. Relevant Advances in Atrial Fibrillation 6/20/2011. Stroke Prophylaxis
Relevant Advances in Atrial Fibrillation Stroke Prophylaxis Managing Atrial Fibrillation: Tips for the Generalist Antiarrhythmic Drug Therapy Ablation Gregory M Marcus, MD, MAS Assistant Professor of Medicine
More informationPrimary Care Atrial Fibrillation Update: Anticoagulation and Left Atrial Appendage Occlusion. Greg Francisco, MD, FACC
Primary Care Atrial Fibrillation Update: Anticoagulation and Left Atrial Appendage Occlusion Greg Francisco, MD, FACC DISCLOSURES None to declare Estimated 33.5million have AF worldwide (6-7million in
More informationPercutane structurele interventies. Hartoor sluiting (Watchman )
Percutane structurele interventies Dr. Luc Muyldermans Dr. Yves Vandekerckhove Dr. Luc Missault Dr. Daniël Dendooven Dr. Patrick Coussement Prof. Mattias Duytschaever Prof. René Tavernier Dr. Philippe
More informationCase Report Hemostasis of Left Atrial Appendage Bleed With Lariat Device
273 Case Report Hemostasis of Left Atrial Appendage Bleed With Lariat Device Amena Hussain MD, Muhamed Saric MD, Scott Bernstein MD, Douglas Holmes MD, Larry Chinitz MD NYU Langone Medical Center, United
More informationLive in a Box: Left Atrial Appendage Closure Device
Live in a Box: Left Atrial Appendage Closure Device Fayez Bokhari, MD, FRCPC KFAFH, Jeddah Saudi Arabia Joint Saudi Heart Association/SACIS April 18, 2015 News: Interventional Cardiologists harm patients
More informationEndocardial LAA Occlusion: Which Device for Which Patient?
Endocardial LAA Occlusion: Which Device for Which Patient? Roy Beinart, MD Davidai Arrhythmia Center The Leviev Heart Center Sheba Medical Center Sheba Medical Center Tel Hashomer The Leviev Heart Center
More informationLeft-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
Medical Policy Manual Surgery, Policy No. 195 Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Next Review: November 2019 Last Review: January 2019 Effective: February
More informationSafety and efficacy results in the EWOLUTION all-comers LAA closure study: DAPT subgroup
Safety and efficacy results in the EWOLUTION all-comers LAA closure study: DAPT subgroup Martin W. Bergmann, Hüseyin Ince, Stephan Kische, Thomas Schmitz, Felix Meincke, Boris Schmidt, David Foley, Timothy
More informationTHINK OUTSIDE THE PILLBOX
THINK OUTSIDE THE PILLBOX An innovative one-time procedure that reduces the risk of stroke in your non-valvular atrial fibrillation (NVAF) patients and the long-term risk of bleeding that comes with a
More informationLeft Atrial Appendage Closure for Atrial Fibrillation 2015 UPDATE
Left Atrial Appendage Closure for Atrial Fibrillation 2015 UPDATE Adam Greenbaum, MD NCVH Detroit 2015-09-12 Disclosures Former proctor: SentreHEART Discussion may include the use of non-fda approved devices
More informationChapter 76 Left Atrial Appendage Closure: Indication and Technique
Chapter 76 Left Atrial Appendage Closure: Indication and Technique RANJAN SHETTY INTRODUCTION Atrial fibrillation (AF) is one of the most common cardiac arrhythmias, which affects around 3% 5% of the population
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationLeft Atrial Appendage Closure: Neurological events
Left Atrial Appendage Closure: Neurological events Medical Director- Foundation for Cardiovascular Medicine San Diego, CA Director Advanced Interventional Therapies- Gagnon Cardiovascular Institute, Morristown,
More informationWatchman and Structural update..the next frontier. Ari Chanda, MD Cardiology Associates of Fredericksburg
Watchman and Structural update..the next frontier Ari Chanda, MD Cardiology Associates of Fredericksburg Different Left Atrial Appendage (LAA) morphologies Watchman (the device) Fabric Anchors Device structure
More informationUpdate in the Management of Atrial Fibrillation
Update in the Management of Atrial Fibrillation Gregory M Marcus, MD, MAS Associate Professor of Medicine Division of Cardiology University of California, San Francisco Disclosures Research: Gilead, Medtronic,
More informationLeft Atrial Appendage Closure: Techniques and Guidelines. Mohammad Shenasa, MD Heart & Rhythm Medical Group San Jose, CA
Left Atrial Appendage Closure: Techniques and Guidelines Mohammad Shenasa, MD Heart & Rhythm Medical Group San Jose, CA May is Stroke Awareness Month 2 September is AF Awareness Month Lecture Highlights
More informationShow Me the Outcomes!
Show Me the Outcomes! Real-World Safety Data on Oral Anticoagulants in Nonvalvular Atrial Fibrillation Gabby Anderson, PharmD PGY1 Pharmacy Resident anderson.gabrielle@mayo.edu Pharmacy Grand Rounds October
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Percutaneous Left Atrial Appendage Closure Device Page 1 of 22 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Percutaneous Left Atrial Appendage Closure Devices
More informationLEFT ATRIAL APPENDAGE CLOSURE INSTEAD OF ANTICOAGULATION; INDICATIONS AND OUTCOMES. Sheetal Chandhok, MD
LEFT ATRIAL APPENDAGE CLOSURE INSTEAD OF ANTICOAGULATION; INDICATIONS AND OUTCOMES Sheetal Chandhok, MD Disclosures Boston Scientific: Speaker (Watchman) Trainer (Watchman) SentreHeart Primary Investigator
More informationTREATMENT OF STROKE PATIENTS THAT ARE TAKING NOVEL ANTICOAGULANTS. Jesse Weinberger, MD The Icahn School of Medicine at Mount Sinai
TREATMENT OF STROKE PATIENTS THAT ARE TAKING NOVEL ANTICOAGULANTS Jesse Weinberger, MD The Icahn School of Medicine at Mount Sinai Acknowledgement Many of the slides for this presentation were obtained
More informationThe Poor Long-Term Candidate for Warfarin: NOAC or Left Atrial Appendage Closure?
The Poor Long-Term Candidate for Warfarin: NOAC or Left Atrial Appendage Closure? Suneet Mittal, MD, FACC, FHRS Director, Electrophysiology Laboratory Valley Health System Ridgewood, NJ and New York, NY
More informationAtrial fibrillation (AF) affects approximately 33 million
Emerging Options for Anticoagulation in LAA Closure Managing anticoagulation and antiplatelet therapy in patients undergoing percutaneous left atrial appendage closure with the Watchman device. BY JESSICA
More informationWhich System Is better?: Watchman or Cardiac Plug or Something Else?
ANGIOPLASTY SUMMIT-TCTAP 2012 Seoul, Korea, April 24-27, 2012 Which System Is better?: Watchman or Cardiac Plug or Something Else? Horst Sievert, Annkathrin Brauth, Isabel Schulmeyer, Patrick Boehm, Jonas
More informationLeft atrium appendage closure: A new technique for patients at high hemorrhagic risk
Left atrium appendage closure: A new technique for patients at high hemorrhagic risk Victoria Martin Yuste MD PhD ITC. Cardiology Department. Hospital Clinic. Barcelona SITE. Barcelona, Juin-9-2013 NON
More informationAtrial Fibrillation. Atrial Fibrillation
Atrial Fibrillation Stroke and Blood Thinning Medications What else is available? Srinivas Iyengar, MD, FACC, with Boulder Heart Structural Heart Director, Boulder Community Health 303-622-5849 Atrial
More informationModern management of atrial fibrillation, from blood pressure control to anticoagulation
Modern management of atrial fibrillation, from blood pressure control to anticoagulation Adel Khalifa S. Hamad, BMS, MD, FRCP(Canada) Consultant Cardiologist & Interventional Cardiac Electrophysiologist
More informationTechnology Assessment Report No. 302
Technology Assessment Report No. 302 Economic Analysis of Left Atrial Appendage Closure for patients with atrial fibrillation, high stroke risk, and contraindicated to anticoagulants Last updated May 2018
More informationCombined catheter ablation and left atrial appendage closure as a. treatment of atrial fibrillation
Combined catheter ablation and left atrial appendage closure as a hybrid procedure for the treatment of atrial fibrillation Giulio Molon, MD FACC, FESC, Fellow ANMCO Card Dept, S.Cuore hospital Negrar
More informationSURGICAL VS ELECTROPHYSIOLOGICAL INTERVENTIONS FOR CARDIAC ARRHYTHMIAS DEBATE 2: LAA CLOSURE IS BEST DONE WITH DEVICES
SURGICAL VS ELECTROPHYSIOLOGICAL INTERVENTIONS FOR CARDIAC ARRHYTHMIAS DEBATE 2: LAA CLOSURE IS BEST DONE WITH DEVICES Dr. Marco Barbierato Interventional Cardiology Cardio-Thoraco-Vascular Department
More informationModern aspects in multidisciplinary thromboembolic prophylaxis. AMPLATZER Left Atrial Appendage data update
Modern aspects in multidisciplinary thromboembolic prophylaxis AMPLATZER Left Atrial Appendage data update Igal Moarof, MD Interventional Cardiology Kantonsspital Aarau Potential conflicts of interest
More informationATRIAL SEPTAL CLOSURE AND LEFT ATRIAL APPENDAGE OCCLUSION: INDICATIONS AND GUIDANCE ECHOCARDIOGRAPHY IN INTERVENTIONAL CARDIOLOGY
ATRIAL SEPTAL CLOSURE AND LEFT ATRIAL APPENDAGE OCCLUSION: INDICATIONS AND GUIDANCE Aristides G. Panlilio, MD, FPCP, FPCC,FPSE, FASE Philippine Heart Center Chinese General Hospital and Medical Center
More informationWATCHMAN PROTECT AF Study Rev. 6
WATCHMAN PROTECT AF Study Rev. 6 Protocol Synopsis Title WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation (PROTECT AF) Sponsor Atritech/Boston Scientific
More informationDad needed to get off his blood thinner. His doctor told us about an alternative. It s called
Dad needed to get off his blood thinner. His doctor told us about an alternative. It s called A one-time procedure that may reduce stroke risk for a lifetime in people with AFib not caused by a heart valve
More informationContinuing Cardiology Education
Continuing Cardiology Education REVIEW ARTICLE Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: indications diversity and future perspectives A. Tzikas 1 & T.
More information16th ANGIOPLASTY SUMMIT-TCTAP TCTAP 2011 Seoul, Korea, April 27 29, 2011 Left Atrial Appendage Closure State of the Art Horst Sievert, Nina Wunderlich, Maik Gonzaga, Annkathrin Braut, Ilona Hofmann CardioVascular
More informationA PATIENT S GUIDE TO THE LEFT ATRIAL APPENDAGE CLOSURE. Reducing the risk of stroke in atrial fibrillation
A PATIENT S GUIDE TO THE LEFT ATRIAL APPENDAGE CLOSURE Reducing the risk of stroke in atrial fibrillation TABLE OF CONTENTS IMPORTANT Please Note: Information provided by Boston Scientific Corporation
More informationManuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de
When not to exclude the LAA Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de Barcelona mcaste@clinic.ub.es @mcastellamd Normal hearts Patient in sinus rhythm Patient in AF (with
More informationNON SURGICAL TREATMENT OF CARDIAC DISEASE PETER J SABIA, MD FACC ASSOCIATES IN CARDIOLOGY SILVER SPRING, MARYLAND
NON SURGICAL TREATMENT OF CARDIAC DISEASE PETER J SABIA, MD FACC ASSOCIATES IN CARDIOLOGY SILVER SPRING, MARYLAND TOPICS ATRIAL SEPTAL DEFECT VSD IHSS PERCUTANEOUS AORTIC VALVE PERCUTANEOUS MITRAL VALVE
More informationקוים מנחים לפרפור פרוזדורים - עדכון משה סויסה מרכז רפואי קפלן
קוים מנחים לפרפור פרוזדורים - עדכון משה סויסה מרכז רפואי קפלן INTRODUCTION The prevalence of atrial fibrillation (AF) is approximately 1.5 2% of the general population The arrhythmia is associated: with
More informationAbstract 1 INTRODUCTION ORIGINAL ARTICLE
Received: 5 October 2017 Revised: 2 November 2017 Accepted: 6 November 2017 DOI: 10.1111/jce.13385 ORIGINAL ARTICLE Feasibility of percutaneous left atrial appendage closure using a novel LAmbre occluder
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More informationDisclosures 6/16/2015. Preventing Stroke in Atrial Fibrillation Warfarin Intolerance / Non-Compliance
6/16/2015 Data Behind LAA Closure This is Ready for Prime Time! Vivek Y. Reddy, MD Helmsley Trust Professor of Medicine Director, Cardiac Arrhythmia Service The Mount Sinai Hospital vivek.reddy@mountsinai.org
More informationLeft atrial appendage closure for thromboembolism prevention in patients with atrial fibrillation: advances and perspectives
Review Article Left atrial appendage closure for thromboembolism prevention in patients with atrial fibrillation: advances and perspectives Bin Kong 1,2, Yu Liu 1,2, He Huang 1,2, Hong Jiang 1,2, Congxin
More informationRelevant Advances in Atrial Fibrillation
Gregory M Marcus, MD, MAS Assistant Professor of Medicine Division of Cardiology University of California, San Francisco Relevant Advances in Atrial Fibrillation Stroke Prophylaxis Antiarrhythmic Drug
More informationDevices for Stroke Prevention. Douglas Ebersole, MD Interventional Cardiology Watson Clinic LLP
Devices for Stroke Prevention Douglas Ebersole, MD Interventional Cardiology Watson Clinic LLP Overview Left Atrial Appendage Closure FDA Approved Watchman Investigational Amulet PFO Closure Atrial Fibrillation
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationLeft Atrial Appendage Closure Andrea Robinson, RN, MSN, ACNP
Left Atrial Appendage Closure Andrea Robinson, RN, MSN, ACNP Cardiac Electrophysiology Nurse Practitioner OhioHealth Heart & Vascular Physicians Riverside Methodist Hospital none Disclosures Atrial Fibrillation
More informationICE 2012 Ioannina,
ICE 2012 Ioannina, 15-12-2012 Case presentation Left Atrial Appendage Occlusion therapy for Stroke Prevention in Atrial Fibrillation Apostolos Tzikas MD, PhD, FESC Interventional Cardiology Congenital
More informationReview Article Thromboembolism Prevention via Transcatheter Left Atrial Appendage Closure with Transeosophageal Echocardiography Guidance
Hindawi Publishing Corporation rombosis Volume 2014, Article ID 832752, 6 pages http://dx.doi.org/10.1155/2014/832752 Review Article Thromboembolism Prevention via Transcatheter Left Atrial Appendage Closure
More informationPercutaneous Mitral Valve Repair
Percutaneous Mitral Valve Repair MitraClip: Procedure, Data, Patient Selection Chad Rammohan, MD FACC Director, Cardiac Cath Lab El Camino Hospital Mountain View, California Mitral Regurgitation MitraClip
More information[N] = No product variation, policy applies as stated [Y] = Standard product coverage varies from application of this policy, see below
Original Issue Date (Created): July 26, 2011 Most Recent Review Date (Revised): November 26, 2013 Effective Date: February 1, 2014 I. POLICY The use of percutaneous left-atrial appendage closure devices
More informationI, (Issam Moussa) DO NOT have a financial interest/arrangement t/ t or affiliation with one or more organizations that could be perceived as a real
PFO Closure: Where We Are Going to after CLOSURE I Study? Issam D. Moussa, MD Professor of Medicine Chair, Division of Cardiovascular Diseases Mayo Clinic Jacksonville, Florida Disclosure Statement of
More informationCatheter Ablation of Atrial Fibrillation in Patients with Prosthetic Mitral Valve
Catheter Ablation of Atrial Fibrillation in Patients with Prosthetic Mitral Valve Luigi Di Biase, MD, PhD, FHRS Senior Researcher Texas Cardiac Arrhythmia Institute at St. David s Medical Center, Austin,
More informationNEW APPROACHES AND NEW ANTICOAGULANTS FOR ATRIAL FIBRILLATION
NEW APPROACHES AND NEW ANTICOAGULANTS FOR ATRIAL FIBRILLATION MAY 1, 2015 Melissa R. Robinson, MD FACC FHRS CCDS Assistant Professor of Medicine Director of the Complex Arrhythmia Service POINTS TO MAKE
More informationDisappearing LAA Thrombus Resulting in Stroke Parekh A, Parekh Ezekowitz M et al: Circ 1 Ezekowitz 14:e513, 2006 M et al: Circ 1
LAA Ablation for Atrial Fibrillation Saudi Heart ACC Riyadh, Saudi Arabia February 2011 David R. Holmes, MD Mayo Clinic Rochester, MN Presenter Disclosure Information David R. Holmes, Jr., M.D. LAA Ablation
More informationAntithrombotic Efficacy and Safety of Dabigatran Etexilate
130419 Luncheon Symposium_2013 춘계심장학회 Antithrombotic Efficacy and Safety of Dabigatran Etexilate Hui-Nam Pak, MD, PhD. Division of Cardiology Yonsei University Health System Atrial Fibrillation Risk of
More informationWatchman Implantation Case Presentation and Discussion
Watchman Implantation Case Presentation and Discussion Walid Saliba, MD, FHRS Director Atrial Fibrillation Center Co-Director AF Stroke Prevention Center Cleveland Clinic Indication FDA NonValvular AF
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More information